A breakthrough respiratory monitoring device incorporating novel nanotechnology-based sensors

Informations projet

SenseGuard

N° de convention de subvention: 946598

DOI

10.3030/946598

Projet clôturé

Date de signature de la CE 26 Mars 2020

Date de début 1 Avril 2020

Date de fin 31 Mars 2023

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 3 567 185,00

Contribution de l’UE

€ 2 497 029,50

Coordonné par

NanoVation-GS
Israel

Periodic Reporting for period 2 - SenseGuard (A breakthrough respiratory monitoring device incorporating novel nanotechnology-based sensors)

Période du rapport: 2021-04-01 au 2023-03-31

Résumé du contexte et des objectifs généraux du projet

Disease monitoring is key for patients with chronic respiratory conditions. Chronic Obstructive Pulmonary Diseases (COPD) is a long-term condition that causes inflammation in the lungs, making breathing difficult. It is a large growing public health problem, expected to become the third leading causes of death by 2030. Nevertheless, COPD patients lack of a frequent and accurate monitoring throughout their disease. This can result in non-adequate therapeutic measures, which can often lead to potential serious effects on patient’s status and high costs for healthcare systems.
To address this massive, worldwide problem, NanoVation’s goal – during the EIC Accelerator project - is to market a clinically validated SenseGuard™. SenseGuard™ is a breakthrough solution, for reliably monitoring of patients with respiratory diseases, including COPD, leveraging a unique nanosensor-based technology. It is an innovative wireless wearable device that enables continuous and non-invasive monitoring of lung functions derived from patients' tidal (normal) breathing.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

NanoVation has finalised the new generation design and developed the hardware and software for optimum performance. The company has also increased its production capacity, meeting its daily production target. NanoVation has commenced the validation activities (including patient recruitment for the clinical trials) and will continue to focus on it in the upcoming months.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Chronic respiratory diseases such as COPD, receive little attention and funding in comparison with other major causes of global morbidity and mortality. Accurate, constant monitoring of COPD patients is crucial to manage exacerbation and minimise outcome severity and costly intervention. Once commercialised, SenseGuard™ will contribute to effective management, therapies and treatment, which will also lead to decreased healthcare costs. By remotely monitoring COPD patients at home, SenseGuard™ will help to reduce admissions in hospitals and thus associated costs for healthcare facilities, thanks to early detection and timely intervention.

nv-logo-new.png